1Ryan C J, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale[J]. Urol Oneo12006, 24(3): 250-253.
2Ning YM, Gulley J, Arlen P, et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-resistant prostate eancer(mCRPC)[J]. J Clin Oncol. 2008,26(15):250.
3Di Lorenzo G, Figg W, Fossa S, et al. Combination of bevacizumab and docetaxel in docetaxel -pretreated hormone-refractory prostate cancer: a phase 2 study[J]. Eur Urol. 2008; 54: 1089-1096.
4Eymard J, Oudard S, Gravis G, et al. Second-line chemotherapy with doeetaxel(D) in men treated with doeetaxel-based regimen for metastatic hormone-refractory prostate caneer(mHRPC). Presented at: the 2007 Prostate Cancer Symposium; Abstract 249,.
